Sagimet Biosciences (NASDAQ:SGMT) just reported results for the first quarter of 2024.
- Sagimet Biosciences reported earnings per share of -23 cents. This was above the analyst estimate for EPS of -40 cents.
- The company did not report any revenue for the quarter.